Genenta Science S.p.A. announced a second amendment to its agreement with AGC Biologics S.p.A., effective December 24, 2024, to enhance manufacturing services for cell therapy products, with specific commitments on manufacturing capacity starting in early 2025. Under this amendment, AGC will reserve an exclusive manufacturing suite and outline penalties for unfulfilled commitments regarding production volume.